{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:52:51Z","timestamp":1793641971369,"version":"4.5.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3 on T cells. The MagnetisMM-1 trial evaluated its safety, pharmacokinetics and efficacy. Primary endpoints, including the incidence of dose-limiting toxicities as well as objective response rate (ORR) and duration of response (DOR), were met. Secondary efficacy endpoints included progression-free survival (PFS) and overall survival (OS). Eighty-eight patients with relapsed or refractory MM received elranatamab monotherapy, and 55 patients received elranatamab at efficacious doses. Patients had received a median of five prior regimens; 90.9% were triple-class refractory, 29.1% had high cytogenetic risk and 23.6% received prior BCMA-directed therapy. No dose-limiting toxicities were observed during dose escalation. Adverse events included cytopenias and cytokine release syndrome. Exposure was dose proportional. With a median follow-up of 12.0\u2009months, the ORR was 63.6% and 38.2% of patients achieving complete response or better. For responders, the median DOR was 17.1\u2009months. All 13 patients evaluable for minimal residual disease achieved negativity. Even after prior BCMA-directed therapy, 53.8% achieved response. For all 55 patients, median PFS was 11.8\u2009months, and median OS was 21.2\u2009months. Elranatamab achieved durable responses, manageable safety and promising survival for patients with MM. ClinicalTrials.gov Identifier:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03690193?term=NCT03269136\">NCT03269136<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02589-w","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:02:13Z","timestamp":1696248133000},"page":"2570-2576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin L.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Y.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Damore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasia","family":"Skoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-6352","authenticated-orcid":false,"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dalovisio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi, U. H. et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266\u20132275 (2019).","journal-title":"Leukemia"},{"key":"2589_CR2","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","volume":"10","author":"C Madry","year":"1998","unstructured":"Madry, C. et al. The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily. Int. Immunol. 10, 1693\u20131702 (1998).","journal-title":"Int. Immunol."},{"key":"2589_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah, N., Chari, A., Scott, E., Mezzi, K. & Usmani, S. Z. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985\u20131005 (2020).","journal-title":"Leukemia"},{"key":"2589_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727\u2013738 (2012).","journal-title":"Br. J. Haematol."},{"key":"2589_CR5","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2589_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2589_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"2589_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398, 665\u2013674 (2021).","journal-title":"Lancet"},{"key":"2589_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2589_CR10","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","volume":"18","author":"SH Panowski","year":"2019","unstructured":"Panowski, S. H. et al. Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol. Cancer Ther. 18, 2008\u20132020 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"2589_CR11","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi, N. C. et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 4, 5988\u20135999 (2020).","journal-title":"Blood Adv."},{"key":"2589_CR12","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje, N. S. et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 9, e143\u2013e161 (2022).","journal-title":"Lancet Haematol."},{"key":"2589_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2589_CR14","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013e548 (2014).","journal-title":"Lancet Oncol."},{"key":"2589_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"2589_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1177\/1740774510382799","volume":"7","author":"Y Ji","year":"2010","unstructured":"Ji, Y., Liu, P., Li, Y. & Bekele, B. N. A modified toxicity probability interval method for dose-finding trials. Clin. Trials 7, 653\u2013663 (2010).","journal-title":"Clin. Trials"},{"key":"2589_CR17","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan, E. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"2589_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper, C. J. & Pearson, E. S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26, 404\u2013413 (1934).","journal-title":"Biometrika"},{"key":"2589_CR19","doi-asserted-by":"crossref","unstructured":"Kalbfleisch, J. D. & Prentice, R. L. The Statistical Analysis of Failure Time Data (Wiley, 2002).","DOI":"10.1002\/9781118032985"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02589-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02589-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02589-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:06:31Z","timestamp":1697436391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02589-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02589-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.J.B. received grant support from Celgene and Janssen; consulting fees from Janssen, Celgene, Amgen, Sanofi, Takeda, Pfizer and Karyopharm Therapeutics; and honoraria from Celgene, Janssen, AbbVie, Amgen, Sanofi, Takeda, Karyopharm Therapeutics, GlaxoSmithKline and Genentech\/Roche. C.L.C. received grant support from Takeda, Celgene and Janssen and consulting fees and honoraria from Celgene, Janssen, Pfizer and Takeda. N.S.R. received grant support from Two Seventy Bio; consulting fees and honoraria from Amgen, Bristol Myers Squibb, Celgene, Janssen, Merck, GlaxoSmithKline and Takeda; and honoraria from Research to Practice and Medscape. M.Y.L. received grant support, consultancy and honoraria from AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Sanofi, Seattle Genetics and Takeda. B.D. received institutional grant support from Takeda, Janssen, Angiocrine, Pfizer, Poseida, Orca Bio, Molecular Template, Bristol Myers Squibb and MEI Pharma and consulting fees from Jazz Pharmaceuticals, Arivan Research and Gamida Cell. M.S. received grant support from ADCT Therapeutics and Partner Therapeutics; consulting fees and honoraria from Bristol Myers Squibb, Seattle Genetics and Pfizer; and honoraria from GlaxoSmithKline, Bristol Myers Squibb and Amgen. M.A.D., S.J., C.B., A.S. and E.M.C. are employed by Pfizer and hold stock or stock options in Pfizer. S.T. received grant support from Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen and Pfizer; consulting fees from Amgen, Bristol Myers Squibb and GlaxoSmithKline; and honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Janssen, Karyopharm Therapeutics, Pfizer, Sanofi and Takeda. A.J. received consulting fees and honoraria and holds membership on boards of directors or advisory committees for AbbVie, Amgen, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Millennium, Sanofi, SkylineDx and Takeda. C.G. received grant support from Celgene; consulting fees and honoraria from Bristol Myers Squibb, Celgene and Janssen; and honoraria from Takeda. M.P.C. received grant support from Celgene and Bristol Myers Squibb and consulting fees and honoraria from Amgen, AstraZeneca, Celgene\/Bristol Myers Squibb, Gilead, Janssen and Teva. M.S. received grant support from Janssen and consulting fees and honoraria from Bristol Myers Squibb, Takeda, Novartis, Karyopharm Therapeutics, Sanofi and Amgen. A.M.L. received institutional grant support from Bristol Myers Squibb, Genentech, Trillium Therapeutics, Sanofi, Pfizer and Janssen Oncology; consulting fees and honoraria from Bristol Myers Squibb, Pfizer and Trillium Therapeutics; honoraria from Bristol Myers Squibb, Genmab, Amgen and Janssen; and patents\/royalties from Serametrix. M.H.T. and A.D. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}